Helus Pharma Inc.

Helus Pharma Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

As of June 30, 2026, Helus Pharma Inc. has 61.98M shares outstanding.

As of June 30, 2026, Helus Pharma Inc. maintains a current ratio of 10.97, meaning it holds 11.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Helus Pharma Inc. posted a negative return on equity (ROE) of -96.38, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -82.40, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 75.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Helus Pharma Inc. generated - - in revenue and converted that into -147.21M in net income, yielding earnings per share of -3.48. EBITDA reached -143.58M, while operating income came in at -143.68M.

These figures are as of June 30, 2026. Total book value stands at 211.90M, with working capital of 153.29M providing operational flexibility.

Helus Pharma Inc. produced -121.06M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.26M in capital expenditures, free cash flow totaled -122.32M - equivalent to -2.89 per share.

Helus Pharma Inc.'s most recent stock split took place on September 19, 2024 with a 38:1 split ratio.